These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 15780954

  • 21. Osteoclast differentiation and bone resorption in multicentric reticulohistiocytosis.
    Adamopoulos IE, Wordsworth PB, Edwards JR, Ferguson DJ, Athanasou NA.
    Hum Pathol; 2006 Sep; 37(9):1176-85. PubMed ID: 16938523
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Serotonin regulates osteoclast differentiation through its transporter.
    Battaglino R, Fu J, Späte U, Ersoy U, Joe M, Sedaghat L, Stashenko P.
    J Bone Miner Res; 2004 Sep; 19(9):1420-31. PubMed ID: 15312242
    [Abstract] [Full Text] [Related]

  • 25. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts.
    Chung YH, Chang EJ, Kim SJ, Kim HH, Kim HM, Lee SB, Ko JS.
    J Periodontal Res; 2006 Aug; 41(4):288-96. PubMed ID: 16827722
    [Abstract] [Full Text] [Related]

  • 26. Possible involvement of protein kinases and Smad2 signaling pathways on osteoclast differentiation enhanced by activin A.
    Murase Y, Okahashi N, Koseki T, Itoh K, Udagawa N, Hashimoto O, Sugino H, Noguchi T, Nishihara T.
    J Cell Physiol; 2001 Aug; 188(2):236-42. PubMed ID: 11424090
    [Abstract] [Full Text] [Related]

  • 27. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production.
    Lee SK, Gardner AE, Kalinowski JF, Jastrzebski SL, Lorenzo JA.
    Bone; 2006 May; 38(5):678-85. PubMed ID: 16309985
    [Abstract] [Full Text] [Related]

  • 28. RANKL-RANK signaling in osteoclastogenesis and bone disease.
    Wada T, Nakashima T, Hiroshi N, Penninger JM.
    Trends Mol Med; 2006 Jan; 12(1):17-25. PubMed ID: 16356770
    [Abstract] [Full Text] [Related]

  • 29. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro.
    Balga R, Wetterwald A, Portenier J, Dolder S, Mueller C, Hofstetter W.
    Bone; 2006 Aug; 39(2):325-35. PubMed ID: 16580896
    [Abstract] [Full Text] [Related]

  • 30. Regulation of human osteoclast differentiation by thioredoxin binding protein-2 and redox-sensitive signaling.
    Aitken CJ, Hodge JM, Nishinaka Y, Vaughan T, Yodoi J, Day CJ, Morrison NA, Nicholson GC.
    J Bone Miner Res; 2004 Dec; 19(12):2057-64. PubMed ID: 15537450
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Jun dimerization protein 2 (JDP2), a member of the AP-1 family of transcription factor, mediates osteoclast differentiation induced by RANKL.
    Kawaida R, Ohtsuka T, Okutsu J, Takahashi T, Kadono Y, Oda H, Hikita A, Nakamura K, Tanaka S, Furukawa H.
    J Exp Med; 2003 Apr 21; 197(8):1029-35. PubMed ID: 12707301
    [Abstract] [Full Text] [Related]

  • 33. RANK ligand and TNF-alpha mediate acid-induced bone calcium efflux in vitro.
    Frick KK, LaPlante K, Bushinsky DA.
    Am J Physiol Renal Physiol; 2005 Nov 21; 289(5):F1005-11. PubMed ID: 15972386
    [Abstract] [Full Text] [Related]

  • 34. Inhibitory effect of CGRP on osteoclast formation by mouse bone marrow cells treated with isoproterenol.
    Ishizuka K, Hirukawa K, Nakamura H, Togari A.
    Neurosci Lett; 2005 Apr 29; 379(1):47-51. PubMed ID: 15814197
    [Abstract] [Full Text] [Related]

  • 35. Dermatan sulfate inhibits osteoclast formation by binding to receptor activator of NF-kappa B ligand.
    Shinmyouzu K, Takahashi T, Ariyoshi W, Ichimiya H, Kanzaki S, Nishihara T.
    Biochem Biophys Res Commun; 2007 Mar 09; 354(2):447-52. PubMed ID: 17239341
    [Abstract] [Full Text] [Related]

  • 36. Inhibition of osteoclast differentiation and bone resorption by tanshinone IIA isolated from Salvia miltiorrhiza Bunge.
    Kim HH, Kim JH, Kwak HB, Huang H, Han SH, Ha H, Lee SW, Woo ER, Lee ZH.
    Biochem Pharmacol; 2004 May 01; 67(9):1647-56. PubMed ID: 15081864
    [Abstract] [Full Text] [Related]

  • 37. Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway.
    Huang H, Chang EJ, Ryu J, Lee ZH, Lee Y, Kim HH.
    Biochem Biophys Res Commun; 2006 Dec 08; 351(1):99-105. PubMed ID: 17052691
    [Abstract] [Full Text] [Related]

  • 38. Inhibition of osteoclast differentiation and bone resorption by a novel lysophosphatidylcholine derivative, SCOH.
    Kwak HB, Lee SW, Li YJ, Kim YA, Han SY, Jhon GJ, Kim HH, Lee ZH.
    Biochem Pharmacol; 2004 Apr 01; 67(7):1239-48. PubMed ID: 15013839
    [Abstract] [Full Text] [Related]

  • 39. Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells.
    Secchiero P, Corallini F, Barbarotto E, Melloni E, di Iasio MG, Tiribelli M, Zauli G.
    J Cell Physiol; 2006 Apr 01; 207(1):158-64. PubMed ID: 16270354
    [Abstract] [Full Text] [Related]

  • 40. Soluble glucocorticoid-induced tumor necrosis factor receptor (sGITR) stimulates osteoclast differentiation in response to receptor activator of NF-kappaB ligand (RANKL) in osteoclast cells.
    Shin HH, Kim SJ, Lee DS, Choi HS.
    Bone; 2005 May 01; 36(5):832-9. PubMed ID: 15814301
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.